What is the treatment for trichomoniasis?

Switch to mobile view »

If you're diagnosed with trichomoniasis, your doctor may prescribe Tindamax®, an oral antibiotic that is effective for treating trichomoniasis.

Treating trichomoniasis with Tindamax®

  • Tindamax is recommended as one of the drugs of choice for the treatment of trichomoniasis by the Centers for Disease Control and Prevention (CDC).
  • In over 30 clinical studies of trichomoniasis, Tindamax has demonstrated cure rates of 92 to 100 percent in both women and men.
  • Tindamax effectively treats trichomoniasis in one dose, while sparing protective vaginal lactobacilli.

Trichomoniasis cure rates with Tindamax®

Chart summarizing cure rates following treatment with Tindamax<sup class='reg'>®</sup>. 96% cure rate was achieved with 2-gram stat oral dosing in female patients. 94% cure rate was achieved with 2-gram stat oral dosing in male patients.

* Average of 4 studies with cure rate range of 92%-100% at 1 week to 1 month postdosing.1-4

** Average of 4 studies with cure rate range of 83%-100%.5-8

Easy, effective treatment in just one dose

Tindamax® is a widely prescribed treatment for TV that requires just one dose to deliver highly effective results.

  • A single 2-gram dose has demonstrated cure rates of 92% to 100% in both women and men.
  • A low risk of side effects, including GI symptoms such as nausea, vomiting, and diarrhea, make Tindamax® easy to tolerate.4

The only therapy approved to treat both BV and TV infections

Bacterial vaginosis and trichomoniasis frequently occur together and may have similar signs and symptoms, including an abnormal vaginal discharge and unpleasant "fishy" odor. Specific tests and laboratory analysis are often used to precisely diagnose BV and TV.5

If your test results indicate that you have a mixed infection, one therapy can treat them both with proven, effective results: Tindamax®.

Important Safety Information

WARNING: POTENTIAL RISK FOR CARCINOGENICITY

Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Its use should be reserved for the conditions described in INDICATIONS AND USAGE.

Contraindications

  • Prior history of hypersensitivity to tinidazole or other nitroimidazole derivatives
  • First trimester of pregnancy
  • Nursing mothers, unless breast-feeding is interrupted during tinidazole therapy and for 3 days following the last dose

Warnings and Precautions

  • Seizures and neuropathy have been reported. Discontinue Tindamax if abnormal neurologic signs develop
  • Vaginal candidiasis may develop with Tindamax and require treatment with an antifungal agent
  • Use Tindamax with caution in patients with blood dyscrasias. Tindamax may produce transient leukopenia and neutropenia

Adverse Reactions

Most common adverse reactions for a single 2 g dose of tinidazole (incidence >1%) are metallic/bitter taste, nausea, weakness/fatigue/malaise, dyspepsia/cramps/epigastric discomfort, vomiting, anorexia, headache, dizziness and constipation. To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-800-298-1087 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.

Please see full Prescribing Information

  1. O-Prasertsawat P, Jetsawangsri T. Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis. 1992 Sep-Oct;19(5):295-7.
  2. Gabriel G, Robertson E, Thin RN. J Int Med Res. 1982;10(2):129-30. J Int Med Res. 1982;10(2):129-30.
  3. Hillström L, Pettersson L, Pálsson E, Sandström SO. Comparison of ornidazole and tinidazole in single-dose treatment of trichomoniasis in women. Br J Vener Dis. 1977 Jun;53(3):193-4.
  4. Aimakhu V. Vaginal trichomoniasis: one stat dose of tinidazole compared with a seven day course of metronidazole. W Afr Med J. 1975 Apr;97-100.
  5. Beric B, Pribicevic V, Djordjevic M, Pavlovic N. Clinical studies on the therapeutic effect of tinidazole ("Fasigyn") during treatment of urogenital trichomonas infections in women and men (with comparative laboratory studies on the effect of metronidazole and tinidazole) Zentralbl Gynakol. 1978;100(24):1594-9.
  6. Massa M, Arias B, Subiabre V, Rojo M. Ensayo terapeutico de la infeccion por Trichomonas vaginalis en el hombre mediate una dosis unica de tinidazol. Bol Chile Parasitol. 1976 Jan-Jun;31(1-2):46-7.
  7. Wallin J, Forsgren A. Tinidazole--a new preparation for T. vaginalis infections. II. Clinical evaluation of treatment with a single oral dose. Br J Vener Dis. 1974 Apr;50(2):148-50.
  8. Fantini E, Leguen J, Kellemberger J, Rubi R. Treatment of trichomoniasis in males with a single dose of a new imidazole derivative. Sem Med. 1974 Jul;46-50.

About Trichomoniasis

» Treatment

More Information

Websites

For Health Professionals

Share on FacebookShare on MySpaceShare on TwitterShare on DiggShare on Yahoo! Buzz
Share on StumbleUponShare on redditShare on TechnoratiShare on del.icio.usShare on LinkedIn

Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).

Clinical Insight

Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»

Beyond BV

Tindamax® may be prescribed for other infections including:

The Mission Pharmacal family of products

Learn more about innovative therapies including...

CitraNatal®Calcium citrate with vital nutrients for mother and baby » Ferralet® 90The iron therapy with biocomplementary absorption » Urocit®-KKidney stone therapy with wax-matrix delivery for slow, sustained release »